An improved LC-MS/MS method for quantitative determination of ilaprazole and its metabolites in human plasma and its application to a pharmacokinetic study

Acta Pharmacologica Sinica

Volumn 30, Issue 9, 2009, Pages 1330-1336

  Zhou, Gan ^a   Tan, Zhi Rong ^a   Zhang, Wei ^a   Ou Yang, Dong Sheng ^a   Chen, Yao ^a   Guo, Dong ^a   Liu, Ying Zi ^a   Fan, Lan ^a   Deng, Han Wu ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Electrospray ionization; Ilaprazole; Ilaprazole sulfone; Ilaprazole thiol ether; LC MS MS; Metabolite; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; ILAPRAZOLE; ILAPRAZOLE SULFONE; ILAPRAZOLE THIOL ETHER; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FLOW RATE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; QUALITY CONTROL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; BENZIMIDAZOLES; CHROMATOGRAPHY, LIQUID; HUMANS; MALE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFOXIDES; YOUNG ADULT;

EID: 70249131462     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.120     Document Type: Article

References (8)

1. Kim EJ, Lee RK, Lee SM, Kim DY. General pharmacology of IY-81149, a new proton pump inhibitor. Arzneimittelforschung 2001; 51: 51-59
2. Periclou AP, Goldwater R, Lee SM, Park DW, Kim DY, Cho KD, et al. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin Pharmacol Ther 2000; 68: 304-311
3. Myung SW, Min HK, Jin C, Kim M, Lee SM, Chung GJ, et al. Identification of IY81149 and its metabolites in the rat plasma using the on-line HPLC/ESI mass spectrometry. Arch Pharm Res 1999; 22: 189-193
4. Li Y, Zhang W, Guo D, Zhou G, Zhou H, Xiao Z. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta 2008; 39: 60-67
5. Taylor PJ. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin Biochem 2005; 38: 328-334
6. Karnes HT, March C. Precision, accuracy, and data acceptance criteria in biopharmaceutical analysis. Pharm Res 1993; 10: 1420-6.
7. Food and Drug Administration. Guidance for Industry on Bioanalytical Method Validation. Fed Regist 2001; 66: 28526-28527
8. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000; 17: 1551-1557